Patient support services programs have become common in the pharmaceutical industry, yet government scrutiny has left some pharma companies wondering what to do with these programs in the future. This POV reviews lays out recommendations from overall business, compliance, legal, and regulatory viewpoints.
It’s been a little over a month since Digital Pharma East’s fall event in Philadelphia, but the takeaways haven’t expired. The conference was packed with insightful sessions; what follows are a few enduring lessons we wanted to share as we head into a new year, brimming with opportunities –
Copay accumulator programs have been a topic of great interest to a number of groups, including managed care organizations, biopharma manufacturers, and patients over the past year. There is no industry standard name for copay accumulators; e.g., UnitedHealthcare and Express Scripts use the terms “Coupon Adjustment: Benefit Plan Protection program”
The Department of Justice reaffirmed its longstanding policy that Title III of the Americans with Disabilities Act (ADA) applies to websites, though once again, it declined to issue specific regulations on what websites need to do to comply with the law. In this POV from our user experience expert, Amy Toft, we explain the importance of accessibility, how adherence to Title III affects websites, and how making content accessible to all users affects pharma.
The oncology space has come a long way in the past five years, so MM&M asked marketing experts – including two from Intouch – to weigh in on where we’ve been and where we’re going. The result is an ebook that discusses recent advancements and gives us a look at what to watch for in the near future.
Frontiers Health draws experts from across the healthcare space to share insights on the latest in digital disruption and technology. For the third annual conference, 45 sessions are planned and will cover everything from digital health for the developing world to patient centricity to blockchain to mindfulness in healthcare to
On October 16, 2018, the Food & Drug Administration (FDA) released a new draft guidance titled Presenting Quantitative Efficacy and Risk Information in Direct-to-Consumer Promotional Labeling and Advertisements. In this POV from Intouch’s external regulatory expert Dale Cooke, we provide an overview of the guidance and offer recommendations for ensuring consumers and healthcare professionals understand promotional communications.
In this POV from Intouch, we discuss the short- and long-term impacts of sharing drug prices with consumers and offer recommendations on how marketers of prescription products should proceed in light of these developments.
Imagine that your best and brightest reps could be given superpowers. Suddenly, they might have the ability to see into the future, or to know what people were thinking. That might not be such a sci-fi fantasy after all. Since 2010, Intouch has been working with Veeva, which offers cloud-based
When the Trump administration announced in May its “blueprint” to lower prescription drug prices — called American Patients First — we were skeptical. Of note in the plan was a proposal to force drug manufacturers to include drug pricing in advertising. At the time, we dismissed it as “not likely